Biotech sector demands regulatory independence for FDA drug review processes

Biotechnology industry stakeholders are calling for safeguards against political interference in FDA drug approval processes as the agency initiates a major hiring and standards-update campaign. The industry emphasizes that regulatory predictability is essential for maintaining investment in clinical research, following recent staffing volatility at the agency.